Last updated: February 23, 2026
What Are the Key Facts of the Case?
Astellas Pharma Inc. filed patent infringement litigation against Sandoz Inc. in the District of New Jersey, case number 1:21-cv-00664, on February 17, 2021. The dispute pertains to the alleged infringement of U.S. Patent No. 10,497,102, which covers a specific formulation of a pharmaceutical compound. Astellas alleges that Sandoz’s proposed biosimilar product infringes on the patent, which claims methods of optimizing drug stability and bioavailability.
The patent expires in 2032. Sandoz has sought FDA approval to market a biosimilar version of the drug, which is used primarily for treatment of heart conditions. The case examines patent validity and infringement questions stemming from the biosimilar's proposed manufacturing process.
What Are the Main Legal Issues?
Patent Validity: Sandoz challenges the '102 patent’s validity, arguing that it fails to meet certain patentability criteria, including novelty and non-obviousness, based on prior art references disclosed before the patent application's filing date.
Infringement: Astellas contends that Sandoz's biosimilar product infringes claims related to formulation stability, which are explicit in the patent. Sandoz disputes that their biosimilar infringes any claim and maintains that their manufacturing process does not violate the patent's scope.
Declaration and Injunctive Relief: Astellas seeks a ruling that Sandoz’s product infringes the patent and an injunction to prevent market entry until the patent expires.
What Are the Procedural Developments?
Since filing in early 2021, the case has undergone preliminary motions, including:
-
Sandoz’s Motion to Dismiss: Filed in June 2021, arguing the patent is invalid for obviousness and improperly granted due to lack of patentable subject matter. This motion remains pending as of the latest update.
-
Astellas’s Motion for Preliminary Injunction: Filed in September 2021, seeking to halt the launch of Sandoz’s biosimilar pending case resolution, based on potential irreparable harm and likelihood of success on the patent infringement claim. The court denied the preliminary injunction in December 2021, citing insufficient proof of immediate harm.
Discovery Process: Began in late 2021, involving technical depositions, patent claim construction proceedings, and review of manufacturing process details.
Claim Construction: Judge has scheduled a Markman hearing for March 2023 to clarify claim scope, critical for infringement analysis.
What Are the Strategic Implications?
The case highlights the ongoing tension between innovator companies and biosimilar entrants. Patent validity challenges could set precedents affecting biosimilar patent litigations, especially regarding formulation patents. The outcome may influence Sandoz’s ability to launch in 2023 or 2024 and could impact licensing negotiations.
Astellas aims to enforce patent exclusivity, while Sandoz seeks to undermine patent strength to expedite biosimilar entry. The case also underscores challenges in patent validity assessments, especially in complex biologics patents.
Comparison to Similar Cases:
- Amgen v. Sandoz (2017): Patent validity debated in biosimilars, with court emphasizing detailed claim construction.
- AbbVie v. Mylan (2020): Patent infringement claims threatened biosimilar market entry, similar to this dispute.
Key Dates Summary
| Date |
Event |
| February 17, 2021 |
Case filed in District of New Jersey |
| June 2021 |
Sandoz motions to dismiss filed |
| September 2021 |
Astellas filed for preliminary injunction |
| December 2021 |
Court denied preliminary injunction |
| March 2023 |
Scheduled Markman hearing |
Anticipated Outcomes
The case’s resolution hinges on the validity of the '102 patent and the scope of infringement. If the court finds the patent valid and Sandoz infringes, injunctive relief or damages could ensue, delaying biosimilar market entry. Conversely, a ruling invalidating the patent would weaken Astellas's exclusivity and facilitate biosimilar approval.
Key Takeaways
- The litigation exposes the critical role of patent validity challenges in biosimilar disputes.
- The outcome may influence patent strategies, particularly around formulations used in biologics.
- Patent scope interpretation during the Markman hearing will significantly shape infringement decisions.
- The case underscores the importance of early patent clearance and thorough validity assessments for biologic compounds.
- Sandoz’s ability to launch biosimilars in 2023-2024 will largely depend on court rulings related to patent validity and infringement.
FAQs
1. When is the court expected to rule on patent validity?
The Markman hearing scheduled for March 2023 will guide validity and infringement assessments. Final rulings may follow in mid to late 2023.
2. Can Sandoz launch its biosimilar before a final court decision?
Yes, pending FDA approval, but courts have previously issued preliminary injunctions to delay market entry, which are common in such cases.
3. How does patent validity challenge impact biosimilar development?
Invalidation of key patents can accelerate biosimilar entry, while upheld patents delay market access and extend exclusivity.
4. What is the significance of the Formulation patent in this case?
It covers specific stability and bioavailability features. Its validity strongly affects Sandoz’s infringement claim.
5. Will this case influence future biosimilar patent filings?
Yes. Courts’ rulings on claim scope and validity can influence how patent claims are drafted and challenged in upcoming biologics disputes.
References
[1] U.S. District Court for the District of New Jersey. (2021). Astellas Pharma Inc. v. Sandoz Inc., Case No. 1:21-cv-00664.
